Literature DB >> 33316287

Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Alexis J Bick1, Renate Louw-du Toit2, Salndave B Skosana1, Donita Africander2, Janet P Hapgood3.   

Abstract

Many different forms of hormonal contraception are used by millions of women worldwide. These contraceptives differ in the dose and type of synthetic progestogenic compound (progestin) used, as well as the route of administration and whether or not they contain estrogenic compounds. There is an increasing awareness that different forms of contraception and different progestins have different side-effect profiles, in particular their cardiovascular effects, effects on reproductive cancers and susceptibility to infectious diseases. There is a need to develop new methods to suit different needs and with minimal risks, especially in under-resourced areas. This requires a better understanding of the pharmacokinetics, metabolism, serum and tissue concentrations of progestins used in contraception as well as the biological activities of progestins and their metabolites via steroid receptors. Here we review the current knowledge on these topics and identify the research gaps. We show that there is a paucity of research on most of these topics for most progestins. We find that major impediments to clear conclusions on these topics include a lack of standardized methodologies, comparisons between non-parallel clinical studies and variability of data on serum concentrations between and within studies. The latter is most likely due, at least in part, to differences in intrinsic characteristics of participants. The review highlights the importance of insight on these topics in order to provide the best contraceptive options to women with minimal risks.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Contraception; Metabolism; Pharmacokinetics; Progestin; Serum concentration

Mesh:

Substances:

Year:  2020        PMID: 33316287      PMCID: PMC8122039          DOI: 10.1016/j.pharmthera.2020.107789

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   13.400


  273 in total

1.  Classification and pharmacology of progestins.

Authors:  Adolf E Schindler; Carlo Campagnoli; René Druckmann; Johannes Huber; Jorge R Pasqualini; Karl W Schweppe; Jos H H Thijssen
Journal:  Maturitas       Date:  2008 Sep-Oct       Impact factor: 4.342

2.  Pharmacokinetic observations on medroxyprogesterone acetate administered orally and intravaginally.

Authors:  A Victor; E D Johansson
Journal:  Contraception       Date:  1976-09       Impact factor: 3.375

3.  Pharmacokinetics and bioavailability of ST 1435 administered by different routes.

Authors:  G Noé; A Salvatierra; O Heikinheimo; X Maturana; H B Croxatto
Journal:  Contraception       Date:  1993-12       Impact factor: 3.375

4.  In Vivo Formation of Ethinylestradiol After Intramuscular Administration of Norethisterone Enantate.

Authors:  Christian Friedrich; Matthias Berse; Stefan Klein; Beate Rohde; Joachim Höchel
Journal:  J Clin Pharmacol       Date:  2018-03-09       Impact factor: 3.126

Review 5.  Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception.

Authors:  Donita Africander; Nicolette Verhoog; Janet P Hapgood
Journal:  Steroids       Date:  2011-03-15       Impact factor: 2.668

6.  Receptor binding of norgestimate--a new orally active synthetic progestational compound.

Authors:  M Juchem; K Pollow; W Elger; G Hoffmann; V Möbus
Journal:  Contraception       Date:  1993-03       Impact factor: 3.375

7.  Pharmacokinetics and protein binding of gestodene under treatment with a low-dose combination oral contraceptive for three months.

Authors:  L Dibbelt; R Knuppen; W Kuhnz; G Jütting
Journal:  Arzneimittelforschung       Date:  1992-09

8.  Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles.

Authors:  W Kuhnz; T Staks; G Jütting
Journal:  Contraception       Date:  1993-12       Impact factor: 3.375

9.  Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations.

Authors:  W Kuhnz; B Schütt; J Power; D J Back
Journal:  Arzneimittelforschung       Date:  1992-09

10.  Drospirenone/ethinyl estradiol 3 mg/20 mug (24/4 day regimen): hormonal contraceptive choices - use of a fourth-generation progestin.

Authors:  Gloria Bachmann; Sharon Kopacz
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more
  6 in total

1.  Radical surgery for pseudo-ovarian malignancy: a case report of bowel endometriosis with massive ascites.

Authors:  Yiting Bao; Wu Huang; Liangqing Yao; Lei Yuan
Journal:  Gland Surg       Date:  2022-05

2.  Differential off-target glucocorticoid activity of progestins used in endocrine therapy.

Authors:  Maleshigo Komane; Chanel Avenant; Renate Louw-du Toit; Donita J Africander; Janet P Hapgood
Journal:  Steroids       Date:  2022-03-07       Impact factor: 2.760

3.  The Progestin Medroxyprogesterone Acetate Affects HIV-1 Production in Human Lymphoid Tissue Explants in a Dose-Dependent and Glucocorticoid-like Fashion.

Authors:  Christophe Vanpouille; Gökçe Günaydın; Mattias Jangard; Mario Clerici; Leonid Margolis; Kristina Broliden; Andrea Introini
Journal:  Viruses       Date:  2021-11-18       Impact factor: 5.048

4.  Medroxyprogesterone acetate inhibits wound closure of human endometrial epithelial cells and stromal fibroblasts in vitro.

Authors:  Mickey V Patel; Marta Rodriguez-Garcia; Zheng Shen; Charles R Wira
Journal:  Sci Rep       Date:  2021-12-01       Impact factor: 4.379

Review 5.  Synthetic Progestins in Waste and Surface Waters: Concentrations, Impacts and Ecological Risk.

Authors:  Maria João Rocha; Eduardo Rocha
Journal:  Toxics       Date:  2022-03-29

6.  Evaluation of the potential for pharmacokinetic interaction between tirabrutinib and levonorgestrel/ethinyl estradiol in healthy female volunteers.

Authors:  Ganesh Cherala; Cara Nelson; Ying Guo; Anubhav Mathur; Thomas Tarnowski; Ahmed A Othman
Journal:  Clin Transl Sci       Date:  2022-03-28       Impact factor: 4.438

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.